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Background: During the last few years, investigators have debated the role that infectious agents may have in
sarcoidosis pathogenesis. With the emergence of new molecular biology techniques, several studies have been
conducted; therefore, we performed a meta-analysis in order to better explain this possible association.
Methods: This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement from the Cochrane collaboration guidelines. Four different databases (Medline,
Scopus, Web of Science, and Cochrane Collaboration) were searched for all original articles published from 1980 to
2015. The present meta-analysis included case–control studies that reported the presence of microorganisms in
samples of patients with sarcoidosis using culture methods or molecular biology techniques. We used a random
effects or a fixed-effect model to calculate the odds ratio (OR) and 95% confidence intervals (CI). Sensitivity and
subgroup analyses were performed in order to explore the heterogeneity among studies.
Results: Fifty-eight studies qualified for the purpose of this analysis. The present meta-analysis, the first, to our
knowledge, in evaluation of all infectious agents proposed to be associated with sarcoidosis and involving more
than 6000 patients in several countries, suggests an etiological link between Propionibacterium acnes and
sarcoidosis, with an OR of 18.80 (95% CI 12.62, 28.01). We also found a significant association between sarcoidosis
and mycobacteria, with an OR of 6.8 (95% CI 3.73, 12.39). Borrelia (OR 4.82; 95% CI 0.98, 23.81), HHV-8 (OR 1.47; 95%
CI 0.02, 110.06) as well as Rickettsia helvetica, Chlamydia pneumoniae, Epstein-barr virus and Retrovirus, although
suggested by previous investigations, were not associated with sarcoidosis.
Conclusion: This meta-analysis suggests that some infectious agents can be associated with sarcoidosis. What
seems clear is that more than one infectious agent might be implicated in the pathogenesis of sarcoidosis;
probably the patient’s geographical location might dictate which microorganisms are more involved. Future
investigations and more clinical trials are need to bring these evidences to a more global level.
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Sarcoidosis is a systemic disorder of unknown origin
that is characterized by the presence of non-caseating
granulomas. With worldwide distribution, more than
one causative agent may be implicated in its pathogen-
esis [1], with numerous infectious and non-infectious
etiological agents having been identified [2]. Currently,* Correspondence: tcesteves990@sapo.pt
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agents have been investigated with inconclusive or con-
flicting results, such as Borrelia burgdorferi, Rickettsia
helvetica, Chlamydia pneumoniae, viruses, fungal infec-
tions, and Leishmania species [3–11].
There are only two relevant meta-analyses in the lit-
erature [12, 13], which address the causal relationship of
some infectious agents in sarcoidosis. Since then, more
than 20 new investigations have been published, thus
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may be involved in sarcoidosis.Methods
Search strategy
This review was conducted in accordance with the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement from the Cochrane
collaboration guidelines. A checklist is available (Add-
itional file 1). Since this study was a literature review
and meta-analysis of previously reported studies, ethical
approval or additional consent from participants was not
required. Four different databases (Medline, Scopus,
Web of Science and Cochrane Database) were searched
for all original articles without language restriction
published from January 1980 to May 2015, using the
search strategy described in online supplementary data
(Additional file 2).Inclusion criteria
The inclusion criteria were as follows: (i) the diagno-
sis of sarcoidosis was made according to the classical
criteria: a compatible clinical and radiological picture,
histopathological demonstration of non-caseating
granulomas with negative stains for mycobacterium
and fungi, and exclusion of other granulomatous dis-
eases; [14] (ii) case–control studies that reported the
presence of microorganisms in samples, both histo-
logical and cellular, of patients with sarcoidosis, using
either culture methods (direct isolation of the organ-
ism) or molecular biology techniques (analysis of
DNA, RNA or proteins); (iii) odds ratios (OR) and
the corresponding confidence intervals (CI) or suffi-
cient information to calculate them; (iv) patients with-
out sarcoidosis were used as a reference group.Exclusion criteria
Studies involving other techniques (e.g. ELISA, immuno-
histochemistry and immunofluorescence) were excluded
from the analysis.Data extraction
First, two independent authors (T. Esteves and V.
Garcia-Patos) reviewed all titles and abstracts. A second
selection was based on a full-text review of potentially
relevant articles and any disagreement was resolved by
discussion between the three authors of this meta-
analysis. A standardized data collection form was used
to extract the following items: author(s), title of article,
study design, year of publication, country of origin, study
size, details of molecular or other techniques used.Statistical analysis and methodological quality
assessment
The measure of interest was the OR and 95% CI calcu-
lated from each study, in order to assess the presence of
microorganisms in sarcoidosis samples versus controls.
Data analyses were performed using Stata Statistical
Software 2015 (StataCorp LP, College Station, Texas,
USA). We used a random-effects model to calculate the
OR and 95% CI from each study [15].
We assessed the heterogeneity among studies using
Cochran’s Q test [16], complemented by the I2-test. [17]
An I2 value of 76–100% represents high heterogeneity,
51–75% moderate heterogeneity and 0–50% low or in-
significant heterogeneity [17]. If the result of the Chi-
square heterogeneity test was not significant (p > 0.10),
we used the fixed-effects model described by Mantel and
Haenszel [18] to calculate the pooled OR estimate.
Additionally, sensitivity and subgroup analyses were




A total of 2465 articles were identified from the ini-
tial electronic search using the outlined search term
parameters (Additional file 2). Among these, 2401
studies were excluded because they did not meet the
inclusion criteria. A total of 64 articles were identi-
fied as investigating the role of infectious agents in
sarcoidosis using either microbial culture or molecu-
lar methods. Six of these were later excluded since
they were descriptive studies without a control
group. Therefore, 58 case–control studies were
qualified for the analysis according to the inclusion
and exclusion criteria. Additional file 3 summarizes
the study flow.
In total, the 58 studies involved 2467 samples from pa-
tients with proven sarcoidosis and 3656 samples from
control patients with other non-sarcoid disorders. All
studies used molecular techniques to identify the differ-
ent types of infectious agents except for two, which used
microbial culture in their analyses [19, 20].
With regard to the infectious agents investigated, 36
studies evaluated the presence of mycobacteria [20–
55] (Table 1), 11 evaluated P. acnes [19, 22, 24, 25,
31, 35, 38, 56–59] (Table 2), seven evaluated human
herpesvirus-8 (HHV-8) [22, 40, 60–64] (Table 3), and
six evaluated Borrelia species [4, 65–69] (Table 4).
Other infectious agents were investigated in some of
the studies included, but there were insufficient cases
to perform a meta-analysis. Three studies evaluated
the presence of Rickettsia species, and one found a
strong association between Rickettsia helvetica and
sarcoidosis [70] (OR 21.72; CI:1.23–384.74). The
Table 1 Case–control studies evaluating the role of mycobacteria in sarcoidosis
First author/Year (Ref.) Country Molecular technique Sarcoidosis patients Non-sarcoidosis controls OR (95% CI)
n/N Type of microorganisms n/N Type of microorganisms
Bocart, 1992 [23] France PCR of 65 kDa mycobacterial
antigen and IS6110
2/22 MTBC 0/22 - 5.49 (0.25–121.18)
Hofland, 2014 [20] Netherlands NAAT for Mycobacteria
and Culture
0/32 - 2/86 1 MTBC, 1NTM 0.52 (0.02–11.13)
Robinson, 2013 [24] USA PCR for 16S rDNA, hsp65
and rpoB
2/30 NTM 1/30 NTM 2.07 (0.18–24.15)
Oswald-Richter, 2012 [25] USA MALDI-IMS for ESAT-6 5/15 Mycobacterium spp 0/4 - 4.71
(0.21–104.49)
Svendsen, 2011 [26] Denmark BD ProbeTec IS6110
amplification
1/52 MTBC 0/50 - 2.94
(0.12–73.93)
Mootha, 2010 [27] India PCR of 65 kDa mycobacterial
antigen and IS6110
13/27 10 MTBC, 3 NTM 2/40 NTM 17.64
(3.53–88.25)
Zhou, 2008 [28] China Real-time PCR of IS986
and human β-blobin gene
20/104 MTBC 7/55 MTBC 1.63
(0.64–4.14)
Dubaniewicz, 2006 [29] Poland BD ProbeTec IS6110
amplification
3/50 MTBC 0/10 - 1.55 (0.07–32.27)
Fite, 2006 [30] Spain PCR of IS6110 and Southern
blot hybridisation
9/23 MTBC 1/23 MTBC 14.14 (1.61–124.11)
Yasuhara, 2005 [31] Japan PCR of IS6110 0/6 - 0/6 - -
Song, 2005 [32] USA PCR of MTB 16S rRNA 6/16 MTBC 0/16 - 20.43 (1.04–401.67)
Marcoval, 2005 [33] Spain NAAT for rRNA of MTBC 0/35 - 0/39 _ -
Yu-Yun Lee, 2002 [34] Taiwan Nested PCR for
mycobacterial hsp65 DNA
7/21 NTM 0/16 - 17.07 (0.89–325.59)
Drake, 2002 [21] USA PCR of 16S rRNA,
rpoB and IS6110
15/25 11 MTBC, 3 NTM, 1 both 0/25 _ 75.29 (4.12–1377.06)
Gazouli, 2002 [22] Greece PCR of IS6110/IS1245/IS900/IS901,
16S rRNA, MPB64 and mtp40
33/46 MTBC 0/20 - 101.74 (5.74–1804.62)
Eish, 2002 [35] Japan PCR of IS6110/IS900 5/108 MTBC 2/86 MTBC 2.04 (0.39–10.78)
Klemen, 2000 [36] Austria PCR of IS6110 and
mycobacterial chaperonin
3/4 NTM 0/39 _ 184.33 (6.26–5425.48)
Li, 1999 [37] USA PCR of 65 kDa mycobacterial
antigen and RFLP analysis
16/20 2 MTBC, 14 NTM 0/20 _ 150.33 (7.54–2997.83)
Ishige, 1999 [38] Japan PCR of IS6110 3/15 MTBC 1/15 MTBC 3.50 (0.32–38.23)
Wilsher, 1998 [39] NZ PCR of IS6110, nested PCR
to amplify 85 bp sequence
within the 123 bp product
0/31 _ 0/10 - -














Table 1 Case–control studies evaluating the role of mycobacteria in sarcoidosis (Continued)
Vokurka, 1997 [41] France PCR of IS6110 and DR region 0/15 _ 0/27 _ -
Ozcelik, 1997 [42] Turkey PCR of IS6110 5/11 MTBC 2/15 MTBC 5.42 (0.81-36.36)
Popper, 1997 [43] Austria PCR of 65 kDa
mycobacterial antigen
and IS6110
11/35 NTM 0/39 - 37.08 (2.09–657.90)
El-Zaatari, 1996 [44] USA PCR of IS900/IS902,
MAC-specific PCR assay
and Western blot
7/7 NTM 13/38 NTM 28.33 (1.50–534.74)
Fidler, 1993 [45] UK PCR of 65 kDa
mycobacterial antigen
and IS6110
7/16 MTBC 1/16 MTBC 11.67 (1.23–110.95)
Thakker, 1992 [46] UK PCR of groEL 1/14 MTBC 1/11 MTBC 0.77 (0.04–13.87)
Gerdes, 1992 [47] Germany PCR of 16S rDNA 0/14 - 0/10 - -
Mitchell, 1992 [48] UK Mycobacterial rRNA
detection by liquid
phase hybridisation
5/5 MTBC 0/5 - 121 (2.02–7259.18)
Saboor, 1992 [49] UK PCR of IS986/IS6110
and groEL
14/20 10 MTBC, 4 NTM 5/22 3 MTBC, 2 NTM 7.93 (1.99–31.59)
Lisby, 1993 [50] Denmark Nested PCR for IS900 0/18 - 0/18 - -
Grosser, 1999 [51] Germany PCR of IS986/IS6110 35/65 MTBC 1/34 MTBC 38.50 (4.96–298.57)
Vago, 1998 [52] Italy PCR of IS6110 2/30 MTBC 0/17 - 3.07 (0.14–67.75)
Richter, 1996 [53] Germany PCR of mycobacterial
16S rDNA
1/24 MTBC 3/57 MTBC 0.78 (0.08–7.93)
Ghossein, 1994 [54] USA PCR of 65 kDa
mycobacterial antigen
0/10 - 0/10 - -
Cannone, 1997 [55] Italy PCR of IS6110 2/30 MTBC 0/10 - 1.84 (0.08–41.62)
n Mycobacteria-positive samples, N total samples, PCR polymerase chain reaction, 65 kDa 65-Kilodalton mycobacteria antigen, IS6110 insertion sequence to identify Mycobacterium tuberculosis complex (MTBC), NTM
non-tuberculous mycobacteria, NAAT nucleic acid amplification test, 16S rDNA ribosomal DNA common to all mycobacteria, rpoB RNA polymerase β-subunit gene, MALDI-IMS matrix-assisted laser desorption ionization
as a mass spectrometry imaging, ESAT-6 6 kDa early secretory antigenic target produced by Mycobacterium tuberculosis, IS986 insertion sequence to identify MTBC, rRNA ribosomal RNA, IS1245/IS900/IS901/IS902 inser-















Table 2 Case–control studies evaluating the role of P. acnes in sarcoidosis
First author/Year (Ref.) Country Molecular technique Sarcoidosis Controls OR (95% CI)
n/N n/N
Robinson, 2013 [24] USA PCR for bacterial 16S rDNA 7/30 1/30 8.83 (1.01–76.96)
Oswald-Richter, 2012 [25] USA MALDI-IMS for propionibacterial proteins 7/15 1/4 2.63 (0.22–31.35)
Yasuhara, 2005 [31] Japan PCR for 16S rRNA 2/6 0/6 7.22 (0.28–189.19)
Gazouli, 2002 [22] Greece PCR for 16S rRNA 0/46 0/20 -
Eish, 2002 [35] Japan PCR for 16S rRNA 93/108 25/86 15.13 (7.39–30.99)
Ishige, 1999 [38] Japan Quantitative PCR for 16S rRNA 12/15 3/15 16 (2.67–95.75)
Negi, 2012 [56] Japan Immunohistochemical methods
(PAG and TIG antibodies) and western blot
149/196 0/79 500.43 (30.44–8226.20)
Yamada, 2002 [57] Japan Quantitative real-time PCR for 16S rRNA 8/9 2/9 28 (2.07–379.25)
Eishi, 1994 [58] Japan PCR for P. acnes DNA 36/39 12/29 17 (4.23–68.28)
Abe, 1984 [19] Japan Isolation of P acnes in culture 31/40 38/180 12.87 (5.65–29.34)
Hiramatsu, 2003 [59] Japan Nested PCR for 16S rRNA 21/30 7/30 7.67 (2.42–24.24)
16S rDNA ribosomal DNA, MALDI-IMS matrix-assisted laser desorption ionization as a mass spectrometry imaging, rRNA ribosomal RNA
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[3] (OR 0.43; CI:0–23.23), while in the third, all real-
time PCR analyses for the detection of Rickettsia were
negative [71]. None of the studies reported a signifi-
cant association with Chlamydia pneumonia [7, 8,
72], Epstein-Barr virus [40], or retrovirus [73].
Meta-analysis
Mycobacteria (Table 1)
Both Mycobacterium tuberculosis complex (MTBC)
and nontuberculous mycobacteria (NTM) were in-
vestigated in most of the 36 relevant studies, al-
though some used primers to detect only M.
tuberculosis [26, 28–33, 38, 39, 41, 42, 51, 52, 55],
and others detected only nontuberculous mycobac-
teria [44, 50].
Figure 1 provides a forest plot for sarcoidosis and myco-
bacteria based on a total of 1034 sarcoidosis patients and
1054 controls. Of the 1034 sarcoidosis cases, 173 were posi-
tive for MTBC, and 58 were positive for NTM. It was not




Knoell, 2005 [60] USA PCR for HHV-8 DNA
Gazouli, 2002 [22] Greece PCR for HHV-8 DNA
Fredricks, 2002 [61] USA PCR for HHV-8 ORF 26 DNA
Maeda, 2000 [62] Japan Hemi-nested PCR for HHV-8 DNA
Sugaya, 1999 [63] Japan Nested PCR for HHV-8 ORF 26 DN
Bélec, 1998 [64] France Nested PCR for HHV-8 ORF 25/26
Di Alberti, 1997 [40] Italy Nested PCR for HHV-8 ORF 26 DN
and Heminested PCR for HHV-8 O
HHV-8 Human Herpesvirus 8, ORF 25/26 DNA insertion sequence to identify HHV-8samples, while both types of mycobacteria DNA were
present in one sample. In total, 250 sarcoidosis sam-
ples were positive for some form of mycobacteria
DNA sequence for a positive signal rate of 24.2%.
We found a significant association between sarcoid-
osis and mycobacteria with an OR of 6.8 (95%
CI:3.73–12.39). A strong association was also found
between sarcoidosis and NTM alone with an OR of
10.39 (95% CI:5.25–20.56), as well as for M. tubercu-
losis complex (OR 4.29; CI:2.60–7.08). There was
moderate heterogeneity among studies (I2 test 52.1%;
p = 0.001), although all but three studies estimated a
risk above unity with significance in most cases.
P. acnes (Table 2)
The risk of sarcoidosis associated with P. acnes was pro-
vided by the study design (Fig. 2). The OR derived from
11 studies with 534 cases and 488 controls was 18.80
(95% CI:12.62–28.01), and there was low heterogeneity
(I2 test 25.9%; p = 0.206). There was a positive signal rate
of 68.54% for P. acnes (366 positive samples from 534rcoidosis





4/119 4/120 1.01 (0.25–4.13)
A 0/12 1/1 0.01 (0.00–0.95)
DNA 0/14 2/17 0.21 (0.01–4.84)
A
RF 25 DNA
38/39 6/113 677.67 (79.01–5812.52)
Table 4 Selected studies on the association between Borrelia species and sarcoidosis
First author/Year
(Ref.)
Country Molecular Technique Sarcoidosis Controls OR (95% CI)
n/N Type of microorganism n/N Type of microorganism
Derler, 2009 [4] Austria Focus-floating microscopy
and Borrelia-specific PCR DNA
13/35 Borrelia sp. 1/61 Borrelia sp. 35.45 (4.38–287.16)
Ishihara, 1998 [65] Japan Dot-blot analysis
(Dotblot Borrelia Kit)
15/46 Borrelia sp. 2/100 Borrelia sp. 23.71 (5.14–109.46)
Martens, 1997 [66] Germany Western blot for
Borrelia burgdorferi
1/60 Borrelia burgdorferi 27/1000 Borrelia burdorferi 0.61 (0.08–4.57)
Lian, 1995 [67] China PCR for Borrelia
burgdorferi DNA
6/49 Borrelia burgdorferi 2/28 Borrelia burgdorferi 1.81 (0.34–9.66)
Xu, 1996 [68] China In situ PCR for
Borrelia burgdorferi DNA
0/23 - 0/23 - -
Ishihara, 1996 [69] Japan Elisa and Dot-blot
analysis for Borrelia sp.
1/38 Borrelia sp. 1/80 Borrelia sp. 2.14 (0.13–35.08)
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samples studied, we found that nine of the 11 studies
[19, 22, 24, 25, 35, 38, 56–58] evaluated the presence
of P. acnes in lymph node samples, of which seven
evaluated this location exclusively [19, 24, 35, 38, 57,
58]. This could justify the low heterogeneity among
studies, contrary to what was observed in the forestFig. 1 Forest plot of studies that show the presence of mycobacteria in saplot of mycobacteria, where the studied biological
samples were more heterogeneous.
Borrelia and HHV-8 (Tables 3 and 4)
Of the six articles assessing the presence of Borrelia in sar-
coidosis tissues, three used polymerase chain reaction
(PCR) techniques for DNA amplification of B. burgdorferircoidosis patients versus controls
Fig. 2 Forest plot of studies that show the presence of P. acnes in sarcoidosis patients versus controls
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cies of Borrelia were involved [4, 65, 69]. The pooled OR
derived from these six studies with 251 cases and 1292 con-
trols was 4.82, but this result did not reach statistical signifi-
cance (95% CI:0.98–23.81). Statistical heterogeneity was
moderate with an I2 of 70% and p = 0.01 Fig. 3 a).
Di Alberti et al [40] were the only ones to report
a significant association between sarcoidosis and
HHV-8 in comparison with controls. However, the
remaining six studies refuted those results [22, 60–
64]. Overall, there was no significant associationFig. 3 Forest plot: a summary OR for the presence of Borrelia species in sar
sarcoidosis patientsbetween sarcoidosis and HHV-8 (OR 1.47; CI:0.02–
110.06), and there was high heterogeneity among
studies (I2 test 92%; p = 0.000) (Fig. 3 b).
Evaluation of publication bias
We performed funnel plots to evaluate publication bias
(Fig. 4). The funnel plots of HHV-8 and mycobacteria
showed evidence of publication bias (Fig. 4b and c),
while the graphs regarding the presence of Borrelia and
P. acnes are fairly symmetrical (Fig. 4a and d). Thus, no
suggestion of publication bias is indicated in these cases.coidosis patients; b summary OR for the presence of HHV-8 in
Fig. 4 Funnel plot of all studies: (a) Borrelia; (b) Herpes; (c) Mycobacteria; (d) P. acnes
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To verify the robustness of the results, as well as the po-
tential sources of heterogeneity, subgroup and sensitivity
analyses were performed (especially for mycobacteria).Subgroup analysis
Concerning the studies of mycobacteria, we conducted
subgroup meta-analysis by various study characteristics
(Table 5). The pooled OR was calculated in subgroups of
studies according to geographical area, publication year,
type of study, and molecular technique used. There was
a significant association between sarcoidosis and myco-
bacteria in all subgroups, except in three studies in-
cluded in the subgroup of molecular techniques (BD
ProbeTec and culture). The pooled OR was significantly
higher with some covariates, however almost all of the
ORs derived from these subgroup data were significantly
above unity.
Through the subgroup analyses, it was noted that the
variables that most influenced the results of heterogen-
eity were: a) the study type, being null the heterogeneity
in the ten prospective studies, contrasting with the mod-
erate heterogeneity in retrospective studies; b) thegeographical location, verifying a low heterogeneity in
studies conducted in the USA and Asia.
Sensitivity analysis
We also performed a sensitivity analysis to complement
the subgroup analysis in order to better explain the het-
erogeneity between studies (Table 5).
Regarding sarcoidosis and mycobacteria, there was a
strong and significant association (OR 4.33; CI:2.06–
9.10) in subgroup analysis of geographic locations when
we restricted to studies performed in countries with low
burden of tuberculosis [24, 30, 35, 38, 40, 42, 44–46, 49,
51, 53]. There was low heterogeneity among these stud-
ies (I2 test 45.7%; p = 0.042) (Table 5).
Another subgroup analysis compared the results ac-
cording to the different biological samples used. Most of
the studies included in our meta-analysis used biological
samples from different locations, including the skin,
lymph nodes, and lungs. However, when we restricted
the analysis to include only studies that performed PCR
on biological samples of the same type, the associations
were also significant in both lung samples [30, 40, 45]
(OR 2.93; CI:1.09–7.86; I2 = 56.9%) and lymph node
samples [24, 35, 38, 40, 46] (OR 3.82; CI:1.53–9.49; I2 =
Table 5 Subgroup and sensitivity analysis of the association between sarcoidosis and mycobacteria
No. of studies OR (95%CI) P-value heterogeneity I2 (%)
Subgroup analysis
1 - Geographical region
Europe 22 6.92 (3.05, 15.71) 0.004 53.8
USA 7 18.21 (4.64, 71.53) 0.238 26.2
Asia 7 4.09 (1.38, 12.12) 0.093 49.8
2 - Publication year
< 2000 20 6.63 (2.84, 15.51) 0.006 54.2
> =2000 16 8.40 (3.31, 21.31) 0.012 53
3 – Type of study
Prospective 10 11.91 (4.94, 28.69) 0.743 0.0
Retrospective 26 6.41 (3.14, 13.09) 0.001 57.1
4 - Molecular technique
PCR 29 7.04 (3.57, 13.89) 0.000 58.8
Hybridization 2 37.81 (3.40, 420.43) 0.484 0.0
Protein analysis 2 12.12 (1.44, 102.20) 0.408 0.0
BD ProbeTec 2 2.09 (0.23, 19.10) 0.776 0.0
Culture 1 0.52 (0.02, 11.13) - -
Sensitivity analysis
1 - Biological samples
Only lymph nodes 11 3.82 (1.53, 9.49) 0.384 4.0
Only lung 5 2.93 (1.09, 7.86) 0.098 56.9
Only skin 2 11.58 (0.06, 2016.91) 0.021 81.3
2 – Incidence of tuberculosis
Only countries with low burden of TB 33 4.33 (2.06, 9.10) 0.042 45.7
CI confidence interval, OR odds ratio, BD ProbeTec molecular detection based on strand displacement amplification (SDA) technology, TB tuberculosis
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11.58; CI:0.06–2016.91; I2 = 81.3%). Once again, the het-
erogeneity among studies was low to moderate except in
two studies performed on skin biopsies (Table 5).
In sensitivity analysis on studies of sarcoidosis and P.
acnes, we found a significant association compared with
the controls when we selected only studies performed
outside Asia [22, 24, 25], with a pooled OR of 5.5 (95%
CI:1.13–27.42) and no heterogeneity among studies.
Discussion
The present meta-analysis is the first to evaluate all in-
fectious agents proposed to be associated with sarcoid-
osis and involving more than 6000 patients in several
countries. The results point to an etiological link be-
tween P. acnes and sarcoidosis with a positive signal rate
of 68.54%. Also, almost one quarter of sarcoidosis pa-
tients show the presence of mycobacteria within the le-
sions. The associations are fairly specific, since P. acnes
(OR 18.80) and mycobacteria (OR 6.8) were significantly
increased in sarcoidosis patients, while Borrelia (OR
4.82; CI:0.98–23.81) and HHV-8 (OR 1.47; CI:0.02–110.06) were not associated with sarcoidosis, contrary to
previous investigations.
Three decades ago, Abe et al [19] reported that P.
acnes was the only bacterium isolated in lymph node bi-
opsy samples taken from sarcoidosis patients. Studies
published in recent years have confirmed that P. acnes
could be a possible infectious agent implicated in the
pathogenesis of sarcoidosis [24, 56, 74–76]. However,
some studies suggest that P. acnes is not specific for sar-
coidosis because it is a normal inhabitant of peripheral
lung tissue and mediastinal lymph nodes, apart from the
skin [77]. Despite this, the results of our meta-analysis
show a significant quantitative difference in the presence
of the P. acnes genome in sarcoidosis patients compared
to control subjects. This suggests that this microorgan-
ism may be present abnormally or may proliferate ectop-
ically in such sarcoid lesions.
However, it is important to note that most of the stud-
ies in our meta-analysis evaluating the role of P. acnes in
sarcoidosis were by Japanese groups testing Japanese pa-
tients, while only very limited data exist for African
American or Caucasian patients [22, 24, 25]. The results
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the pooled OR was above unity and statistically signifi-
cant (5.58; CI:1.13–27.42). Despite these surprising re-
sults, the ORs observed in studies with Japanese patients
were far superior, and the results were more consistent
and robust. Differences between these two groups may
be due to the geographical, ethnic, or racial composition
of the study population. Sarcoidosis in Japanese patients
is characterized by a high rate of ocular, cutaneous, and
cardiac involvement, while in Europe and the USA, this
disease mainly affects the lungs.
In 2002, the first large, relevant study was published as
a collaboration between several countries [35]. The re-
sults of this international study suggest an association
between P. acnes and sarcoidosis in not only Japanese
patients (positive signal rate of 89.2%), but also in Euro-
peans (positive signal rate of 81.4%). However, more
international corporative studies with quantitative PCR
are needed to clarify the role of P. acnes in sarcoidosis
and for better understanding of the phenotypic variabil-
ity of this disease.
Recent years have witnessed substantial discussion
among investigators about the role that mycobacteria
may have in the pathogenesis of sarcoidosis, and the
issue remains unsettled, if not controversial. With the
emergence of new microbiological techniques, especially
in the molecular biology area, several studies have been
conducted in order to investigate this possible associ-
ation more deeply.
In the present meta-analysis, we identified 36 studies
assessing the presence of mycobacteria in a total of 1034
sarcoidosis patients and 1054 controls. The results sug-
gest a strong association of sarcoidosis with NTM (OR
10.39; CI:5.25–20.56) and with MTBC (4.29; CI:2.60–
7.08). However, to evaluate the possible relationship be-
tween mycobacteria and sarcoidosis, the current inci-
dence of tuberculosis should be taken into account in
general populations of the different countries where the
studies of sarcoidosis were performed. In the sensitivity
analyses, a significant association was also found (OR
4.33; CI:2.06–9.10) when we restricted the analysis to in-
clude only studies performed in countries with low
prevalence of tuberculosis. This further confirms the ro-
bustness of the results and the relevance of this associ-
ation worldwide.
Despite the heterogeneity of analyzed studies and the
potential publication bias suggested by the mycobacteria
funnel plots, most of the ORs derived from individual
data were significantly above unity. Furthermore, sensi-
tivity and subgroup analyses including only studies per-
formed on lung samples or lymph nodes showed low
heterogeneity. Therefore, it is important to account for
the heterogeneity in sarcoidosis specimens (lung versus
skin or lymph nodes). We found significant increasedORs in studies performed on lung or lymph node sam-
ples but not in skin specimens. Possible explanations for
this include the following: 1) In the initial phase of the
disease, systemic sarcoidosis primarily affects and
spreads through the lymphatic system, following the
lymphatic vessels to the hilar and mediastinal lymph
nodes. 2) Lung and lymph node samples are obtained
sterilely by endoscopy biopsies and thus avoid possible
microorganism contamination, in contrast to skin biop-
sies. 3) The two studies performed on sarcoidosis skin
samples were both retrospective [37, 40]. In such stud-
ies, there is a greater possibility of both contamination
of the paraffin-embedded specimens and more DNA
fragmentation. In contrast, several studies performed on
lung and lymph node samples were prospective, and
only fresh tissues were used. Additionally, when we con-
ducted the subgroup analysis according to the type of
study, it was found a low heterogeneity in the 10 pro-
spective studies (I2 = 0%), contrasting with the moderate
heterogeneity in retrospective studies (I2 = 57.1%).
The hypothesis that B. burgdorferi could be a possible
causal infectious agent for sarcoidosis was first men-
tioned in 1989 in epidemiological studies [78]. Since
then, several studies have been conducted using sero-
logical or molecular techniques in order to clarify the
role of Borrelia in the pathogenesis of sarcoidosis. We
identified six articles assessing the presence of Borrelia
in sarcoidosis tissues using molecular techniques (251
cases and 1292 controls), and we did not find a signifi-
cant association (OR 4.82; CI:0.98–23.81). On the other
hand, the two studies that reported a significant associ-
ation between Borrelia and sarcoidosis [4, 65] were both
conducted in regions where Lyme disease is endemic, in
contrast to the four other articles performed in non-
endemic areas [66–69], where the results did not reach
statistical significance.
It is important to note that the frequency of exposure
to Borrelia. spirochete is different between patients living
in regions where the disease is endemic and those in re-
gions where it is not. Thus, in countries with elevated B.
burgdorferi prevalence, a protective immunity against
this microorganism has to be assumed in the general
population. T-helper lymphocyte activity to this micro-
organism might be a trigger for the development of sar-
coidosis in endemic regions, which could explain the
positive results in studies published in Austria and Japan
[4, 65]. Apart from these two studies, the fact that sig-
nificant positive PCR results could not be found argues
against the hypothesis of a connection between B. burg-
dorferi infection and sarcoidosis. However, more studies
are needed to clarify the possible association, especially
in endemic areas.
There are several clinical implications of this study.
Currently, immune suppression remains the primary
Esteves et al. BMC Pulmonary Medicine  (2016) 16:165 Page 11 of 13treatment modality for sarcoidosis. Given our meta-
analysis, it is worth exploring whether certain antibacterial
or antimycobacterial drugs might alter the course of sar-
coidosis. In the past, some clinical trials have been pub-
lished with conflicting results using classical
antituberculous drugs, such as isoniazid, amino-salicylic
acid, and streptomycin [79–82]. Recently, Drake et al [83]
conducted a double-blind, placebo-controlled study to in-
vestigate the efficacy of oral antimycobacterial therapy
(levofloxacin, ethambutol, azithromycin, and rifampin) in
patients with cutaneous sarcoidosis. The results were
promising, with significant reductions in cutaneous lesion
size. The same authors also conducted an open-label in-
vestigation using the same therapy regimen in pulmonary
sarcoidosis patients, and the results were again very inter-
esting with significant improvements in forced vital cap-
acity from baseline to completion of therapy [84].
Other antimicrobial agents such as minocycline and
doxycycline have been shown to be quite effective in
treating cutaneous sarcoidosis in some series [85, 86].
However, the exact mechanism of action of these drugs
it is not fully understood [87].
Currently, other clinical trials are being done
(NCT02024555 and NCT01245036) to clarify the role
that antimicrobial agents might have in the treatment of
sarcoidosis.
Several limitations in our study should be recognized.
First, one of the main potential limitations relates to the
variability and heterogeneity of the results analyzed. It is
important to consider that the majority of these studies
were assessed retrospectively and that data were obtained
from different databases and hospitals. This could lead to
different types of bias in the included studies and to vari-
ability in the results. Second, the risk of contamination or
DNA fragmentation in PCR techniques can lead to false
positive or false negative results. In addition, PCR does not
discriminate between living and dead microorganisms.
Third, the patients had varied clinical manifestations of sar-
coidosis; moreover, the non-sarcoidosis controls were com-
prised of different types of subjects across the studies,
which may cause misclassification bias and heterogeneity.
Conclusion
The present meta-analysis, involving more than 6000 pa-
tients from various countries worldwide, suggests a sig-
nificant association between sarcoidosis and some
infectious agents, taking into account the marked differ-
ence in the percentage of microbial DNA-positive sam-
ples in sarcoidosis patients versus controls, especially
mycobacteria (OR 6.8) and P. acnes (OR 18.80). Further-
more, our study also suggests caution regarding a puta-
tive association between sarcoidosis and B. burgdorferi.
What seems clear is that more than one infectious
agent might be implicated in the pathogenesis ofsarcoidosis; probably the patient’s geographical location
might dictate which microorganisms are more involved.
More studies and clinical trials are needed to extend
this evidence to a more global level.
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